Study conduct
melanoma
MELANOMA
The study was initiated on February 27, 2017, and a strategic decision was made on April 11, 2018, to permanently stop enrollment. This decision was based on the results of the Phase III ECHO-301/ KEYNOTE-252 study, which compared epacadostat plus pembrolizumab with placebo plus pembrolizumab in patients with advanced melanoma [ECHO-206 was conducted in accordance with Good Clinical Practice guidelines, the provisions of the Declaration of Helsinki, and applicable national and local regulatory requirements. The study protocol was approved by the independent ethics committee/institutional review board at each participating site, and all patients provided written informed consent.